| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
3 companies
Daniel B Soland last filed a Form 4 in May 2025, as Director at ACAD. The filings on record cover 3 companies. Daniel B Soland's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 44,041 shares of ACAD. Net of sales, the ACAD filings show accumulation of 10,000 shares.
Daniel B Soland has 21 Form 4 filings on record from March 2015 to May 2025, across 3 companies: Director at Acadia Pharmaceuticals (ACAD), 2015–2025; Director at DBV Technologies (DBVT), 2021–2023; Director at KalVista Pharmaceuticals (KALV), 2019–2021.
The 37 reported transactions were 24 option or other derivative awards, 8 open-market purchases and 5 option exercises.
Counted by filing, the open-market trades come to 3 purchases worth about $378K and no sales.
The largest open-market purchase was 10,000 shares of ACAD at an average $23.49 on March 2, 2018, about $235K.
Shares as reported in the last Form 4 for each company; the most recent is from May 2025. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.